EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma

Cancer Discovery

Volumn 5, Issue 3, 2015, Pages 274-287

  Miao, Benchun ^a,b   Ji, Zhenyu ^a,b   Tan, Li ^b,c   Taylor, Michael ^a   Zhang, Jianming ^b   Choi, Hwan Geun ^b,c   Frederick, Dennie T ^a   Kumar, Raj ^a,b   Wargo, Jennifer A ^d   Flaherty, Keith T ^a,e   Gray, Nathanael S ^b,c   Tsao, Hensin ^a,b,e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; EPH TYROSINE KINASE INHIBITOR; EPHRIN RECEPTOR A2; ERYTHROPOIETIN PRODUCING HEPATOCELLULAR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR; UNCLASSIFIED DRUG; VEMURAFENIB; ANTINEOPLASTIC AGENT; B RAF KINASE; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL ASSAY; CELL CULTURE; CELL GROWTH; CELL MIGRATION ASSAY; CELL VIABILITY; CELL VIABILITY ASSAY; CELLULAR COLONY FORMATION ASSAY; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE MUTATION; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC50; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MOUSE; NICK END LABELING; NONHUMAN; PHENOTYPE; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL MOTION; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION; HUMANS; INDOLES; MELANOMA; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPHA2; SULFONAMIDES; TUMOR BURDEN; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84925303187     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-14-0295     Document Type: Article

References (45)

1. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classifi -cation. J Clin Oncol 2009;27:6199–206.
2. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949–54.
3. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Lark in J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507–16.
4. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman J A, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809–19.
5. Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009;27:2823–30.
6. Flaherty K T, Infante JR, Daud A, Gonzalez R, Kef ford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694–703.
7. Tsao H, Chin L, Garraway LA, Fisher DE. Melanoma: from mutations to medicine. Genes Dev 2012;26:1131–55.
8. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24:4340–6.
9. Prickett TD, Agrawal NS, Wei X, Yates KE, Lin JC, Wunderlich JR, et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 2009;41:1127–32.
10. Udayakumar D, Zhang G, Ji Z, Njauw CN, Mroz P, Tsao H. Epha2 is a critical oncogene in melanoma. Oncogene 2011;30:4921–9.
11. Schlegel J, Sambade MJ, Sather S, Moschos SJ, Tan AC, Winges A, et al. MERTK receptor tyrosine kinase is a therapeutic target in melanoma. J Clin Invest 2013;123:2257–67.
12. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468:973–7.
13. Sabbatino F, Wang Y, Wang X, Flaherty KT, Yu L, Pepin D, et al. PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Oncotarget 2014;5:1926–41.
14. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010;18:683–95.
15. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012;487:500–4.
16. Yadav V, Zhang X, Liu J, Estrem S, Li S, Gong XQ, et al. Reactivation of mitogen- activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. J Biol Chem 2012;287: 28087–98.
17. Girotti MR, Marais R, Deja Vu: EGF receptors drive resistance to BRAF inhibitors. Cancer Discov 2013;3:487–90.
18. Girotti MR, Pedersen M, Sanchez-Laorden B, Viros A, Turajlic S, Niculescu-Duvaz D, et al. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov 2013;3:158–67.
19. Vaught D, Chen J, Brantley-Sieders DM. Regulation of mammary gland branching morphogenesis by EphA2 receptor tyrosine kinase. Mol Biol Cell 2009;20:2572–81.
20. Zhuang G, Brantley-Sieders DM, Vaught D, Yu J, Xie L, Wells S, et al. Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res 2010;70:299–308.
21. Ruiz JC, Robertson EJ. The expression of the receptor-protein tyro-sine kinase gene, eck, is highly restricted during early mouse development. Mech Dev 1994;46:87–100.
22. Moore-Scott BA, Opoka R, Lin SC, Kordich JJ, Wells JM. Identifi cation of molecular markers that are expressed in discrete anterior-posterior domains of the endoderm from the gastrula stage to mid-gestation. Dev Dyn 2007;236:1997–2003.
23. Ganju P, Shigemoto K, Brennan J, Entwistle A, Reith AD. The Eck receptor tyrosine kinase is implicated in pattern formation during gastrulation, hindbrain segmentation and limb development. Onco-gene 1994;9:1613–24.
24. Connor RJ, Menzel P, Pasquale EB. Expression and tyrosine phospho-rylation of Eph receptors suggest multiple mechanisms in patterning of the visual system. Dev Biol 1998;193:21–35.
25. Andres AC, Reid HH, Zurcher G, Blaschke RJ, Albrecht D, Ziemiecki A. Expression of two novel eph-related receptor protein tyrosine kinases in mammary gland development and carcinogenesis. Onco-gene 1994;9:1461–7.
26. Easty DJ, Guthrie BA, Maung K, Farr CJ, Lindberg RA, Toso RJ, et al. Protein B61 as a new growth factor: expression of B61 and up-regulation of its receptor epithelial cell kinase during melanoma progression. Cancer Res 1995;55:2528–32.
27. Easty DJ, Hill SP, Hsu MY, Fallowfield ME, Florenes VA, Herlyn M, et al. Up-regulation of ephrin-A1 during melanoma progression. Int J Cancer 1999;84:494–501.
28. Hendrix MJ, Seftor EA, Kirschmann DA, Quaranta V, Seftor RE. Remodeling of the microenvironment by aggressive melanoma tumor cells. Ann N Y Acad Sci 2003;995:151–61.
29. Kamat AA, Coffey D, Merritt WM, Nugent E, Urbauer D, Lin Y G, et al. EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Cancer 2009;115:2684–92.
30. Zelinski DP, Zantek ND, Stewar t JC, Irizarr y AR, Kinch MS. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 2001;61:2301–6.
31. Zhuang G, Brantley-Sieders DM, Vaught D, Yu J, Xie L, Wells S, et al. Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res 2010;70:299–308.
32. Menges CW, McCance DJ. Constitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA2 receptor. Oncogene 2008; 27: 2934–40.
33. Beauchamp A, Debinski W. Ephs and ephrins in cancer: ephrin-A1 signalling. Semin Cell Dev Biol 2012;23:109–15.
34. Fang WB, Brantley-Sieders DM, Parker MA, Reith AD, Chen J. A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis. Oncogene 2005;24:7859–68.
35. Miao H, Burnett E, Kinch M, Simon E, Wang B. Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nature Cell Biol 2000;2:62–9.
36. Kinch MS, Carles-Kinch K. Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer. Clin Exp Metastasis 2003;20:59–68.
37. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 2006;5:1136–44.
38. Miao H, Li DQ, Mukherjee A, Guo H, Petty A, Cutter J, et al. EphA2 mediates ligand- dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell 2009;16:9–20.
39. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotech-nol 2011;29:1046–51.
40. Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner A, et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov 2014;4:61–8.
41. Tandon M, Vemula SV, Mittal SK. Emerging strategies for EphA2 receptor targeting for cancer therapeutics. Expert Opin Ther Targets 2011;15:31–51.
42. Brantley DM, Cheng N, Thompson EJ, Lin Q, Brekken RA, Thorpe PE, et al. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 2002;21:7011–26.
43. Dobrzanski P, Hunter K, Jones-Bolin S, Chang H, Robinson C, Pritch-ard S, et al. Antiangiogenic and antitumor effi cacy of EphA2 receptor antagonist. Cancer Res 2004;64:910–9.
44. Noberini R, Koolpe M, Peddibhotla S, Dahl R, Su Y, Cosford ND, et al. Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors. J Biol Chem 2008;283:29461–72.
45. Yamaguchi S, Tatsumi T, Takehara T, Sakamori R, Uemura A, Mizushima T, et al. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide- pulsed dendritic cell vaccines. Cancer 2007;110:1469–77.